These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fesoterodine: a new agent for treating overactive bladder.
    Author: Ellsworth P, Berriman SJ, Brodsky M.
    Journal: Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800.
    Abstract:
    OBJECTIVE: To review the efficacy and safety of fesoterodine, a new antimuscarinic for treating overactive bladder (OAB) symptoms. METHODS: Review of efficacy and safety data from the pivotal phase 3 trials of fesoterodine for the treatment of OAB. Although there were a number of additional end points, they were not included in the US prescribing information for fesoterodine and thus are not included in this article. RESULTS: OAB is a chronic condition affecting both men and women. The principal symptom is urgency, with or without urgency incontinence, with some patients experiencing increased daytime frequency and nocturia. In two 12-week, randomized, double-blind, phase 3 trials, fesoterodine 4 and 8 mg administered once daily were significantly better than placebo in alleviating OAB symptoms, as determined by changes in bladder diary variables. Both doses of fesoterodine were well tolerated. CONCLUSIONS: Fesoterodine is an efficacious, well-tolerated treatment for OAB.
    [Abstract] [Full Text] [Related] [New Search]